Imagine you or a loved one had an advanced biliary tract cancer – tumors that originate in the bile ducts or gallbladder – and you learn that all of your treatment options have been exhausted. Where do you go from there? New data presented at the 2015 ASCO Annual Meeting, including promising clinical outcomes in biliary tract cancer patients, show that comprehensive genomic profiling with FoundationOne® has significant potential to maximize the identification of new treatment options for these devastating cancers.

Conventional treatment options are often limited for biliary tract cancers and patients face poor prognosis. However, in this study, Foundation Medicine conducted comprehensive genomic profiling of tumor samples from 554 patients with a broad range of advanced biliary tract cancers and determined that two-thirds of patients harbored clinically relevant genomic alterations, which could potentially influence and personalize treatment by guiding the selection of approved targeted therapies or access to therapies in clinical trials. These data are very encouraging for a patient population facing serious unmet medical needs, and provide further support that comprehensive genomic profiling should be incorporated into routine clinical cancer care.

These data, including select case studies highlighting clinical benefit in patients, were presented in an oral presentation at the Annual Meeting titled, “Comprehensive Genomic Profiling Of Biliary Tract Cancers Reveals Tumor-Specific Differences and a High Frequency of Clinically Relevant Genomic Alterations” (abstract #4009), by Dr. Milind Javle, professor in the department of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center.

For more information on the data, see our press release.